Terms: = Cervical cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1
265 results:
1. PD-L1 Immunohistochemical Expression in Endometrial Carcinoma: Egyptian Cross-Sectional Study.
Wahba MG; Soliman SS; Salama ME; Nasr S; Al Shereef ZAE
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1441-1450. PubMed ID: 38680006
[TBL] [Abstract] [Full Text] [Related]
2. Comparison of programmed death-ligand 1 expression in adenocarcinoma and squamous cell carcinoma of the cervix in paraffin blocks of patients with cervical cancer.
Hosseini MS; Shafizadeh F; Bahremani MH; Farzaneh F; Ashrafganjoei T; Arab M; Talayeh M; Jafari F; Abdshah A
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2057. PubMed ID: 38662366
[TBL] [Abstract] [Full Text] [Related]
3. Ultrasound-Triggered Azo Free Radicals for cervical cancer Immunotherapy.
Wang Y; Lv B; Wang H; Ren T; Jiang Q; Qu X; Ni D; Qiu J; Hua K
ACS Nano; 2024 Apr; 18(17):11042-11057. PubMed ID: 38627898
[TBL] [Abstract] [Full Text] [Related]
4. Impact of programmed cell death protein 1 inhibitor therapy on the survival of patients with advanced or recurrent uterine cancers: a meta-analysis.
Liang KW; Chen LJ; Wang CH; Ma KS; Hsia LH; Wang PH
Front Immunol; 2024; 15():1331994. PubMed ID: 38562939
[TBL] [Abstract] [Full Text] [Related]
5. STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-pd-1 therapy resistance.
Li T; Zhang W; Niu M; Wu Y; Deng X; Zhou J
Front Immunol; 2024; 15():1342647. PubMed ID: 38550593
[TBL] [Abstract] [Full Text] [Related]
6. Associations of pd-1 and PD-L1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies.
Yang M; Liu Y; Zheng S; Geng P; He T; Lu L; Feng Y; Jiang Q
Aging (Albany NY); 2024 Mar; 16(7):6068-6097. PubMed ID: 38546391
[TBL] [Abstract] [Full Text] [Related]
7. Three-dimensional chromatin analysis reveals Sp1 as a mediator to program and reprogram HPV-host epigenetic architecture in cervical cancer.
Cao C; Xu Q; Zhu Z; Xu M; Wei Y; Lin S; Cheng S; Zhi W; Hong P; Huang X; Lin D; Cao G; Meng Y; Wu P; Peng T; Wei J; Ding W; Huang X; Sung W; Chen G; Ma D; Li G; Wu P
Cancer Lett; 2024 Apr; 588():216809. PubMed ID: 38471646
[TBL] [Abstract] [Full Text] [Related]
8. New windows of surgical opportunity for gynecological cancers in the era of targeted therapies.
Peters I; Marchetti C; Scambia G; Fagotti A
Int J Gynecol Cancer; 2024 Mar; 34(3):352-362. PubMed ID: 38438181
[TBL] [Abstract] [Full Text] [Related]
9. A first-in-human phase I study of the pd-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101).
Lakhani N; Cosman R; Banerji U; Rasco D; Tomaszewska-Kiecana M; Garralda E; Kornacki D; Li J; Tian C; Bourayou N; Powderly J
ESMO Open; 2024 Apr; 9(4):102254. PubMed ID: 38387109
[TBL] [Abstract] [Full Text] [Related]
10. Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic cervical cancer (COMPASSION-13): A Phase 2 Study.
Lou H; Cai H; Huang X; Li G; Wang L; Liu F; Qin W; Liu T; Liu W; Wang ZM; Li B; Xia Y; Wang J
Clin Cancer Res; 2024 Apr; 30(8):1501-1508. PubMed ID: 38372727
[TBL] [Abstract] [Full Text] [Related]
11. Real-world outcomes of first-line maintenance therapy for recurrent or metastatic cervical cancer: A multi-center retrospective study.
Peng C; Li X; Tang W; Zhu W; Yan P; Chen J; Zhang X; Guo Q; Wu Q; Wang Q; Liu N; Ma A; Lu Y; Lv P; Liu J; Xie P
Int Immunopharmacol; 2024 Mar; 129():111578. PubMed ID: 38330795
[TBL] [Abstract] [Full Text] [Related]
12. Clinical benefit analysis of pd-1 inhibitors in patients with advanced, recurrent or metastatic cervical cancer: a meta-analysis and systematic review.
Wang YZ; Wang JS; Du J; Tang XL; Xiao JP
Front Immunol; 2024; 15():1305810. PubMed ID: 38327524
[TBL] [Abstract] [Full Text] [Related]
13. Clinical significance of integrin αV and β superfamily members and focal adhesion kinase activity in oral squamous cell carcinoma: a retrospective observational study.
Sakurai S; Ishida Y; Shintani T; Yamasaki S; Matsui K; Hamana T; Nobumoto T; Yanamoto S; Hayashido Y
Pathol Oncol Res; 2024; 30():1611571. PubMed ID: 38312516
[No Abstract] [Full Text] [Related]
14. Prevalence of PD-L1 in cervical cancer Patients and the Potential for Combining an Immune Checkpoint Inhibitor With Lenvatinib.
Bräutigam K; Schmidt T; Baur M; Tauber N; Kontomanolis EN; Hemptenmacher F; Rody A; Köster F
Anticancer Res; 2024 Feb; 44(2):503-510. PubMed ID: 38307554
[TBL] [Abstract] [Full Text] [Related]
15. An engineered Accum-E7 protein-based vaccine with dual anti-cervical cancer activity.
Bikorimana JP; Abusarah J; Gonçalves M; Farah R; Saad W; Talbot S; Stanga D; Beaudoin S; Plouffe S; Rafei M
Cancer Sci; 2024 Apr; 115(4):1102-1113. PubMed ID: 38287511
[TBL] [Abstract] [Full Text] [Related]
16. Whether specific genetic feature predicted immunotherapy efficacy: A case report.
Chen J; Pang L; He L; Li T; Cheng X
Medicine (Baltimore); 2024 Jan; 103(2):e36922. PubMed ID: 38215117
[TBL] [Abstract] [Full Text] [Related]
17. Glycolysis Induced by METTL14 Is Essential for Macrophage Phagocytosis and Phenotype in cervical cancer.
Wang B; Mao Z; Ye J; Jiao X; Zhang T; Wang Q; Han S; Zhang Y; Wang C; Dong T; Cui B
J Immunol; 2024 Feb; 212(4):723-736. PubMed ID: 38197667
[TBL] [Abstract] [Full Text] [Related]
18. Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report.
Passarelli A; Pisano C; Coppola E; Ventriglia J; Cecere SC; Di Napoli M; Carideo L; Lastoria S; Pignata S
Front Immunol; 2023; 14():1303893. PubMed ID: 38193091
[TBL] [Abstract] [Full Text] [Related]
19. Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review.
Zhai C; Jin X; You L; Yan N; Dong J; Qiao S; Zhong Y; Zheng Y; Pan H
BMC Geriatr; 2024 Jan; 24(1):32. PubMed ID: 38191289
[TBL] [Abstract] [Full Text] [Related]
20. An Immune Gene Expression Risk Score for Distant Metastases after Radiotherapy for cervical cancer.
Lukovic J; Pintilie M; Han K; Fyles AW; Bruce JP; Quevedo R; Pugh TJ; Fjeldbo CS; Lyng H; Milosevic MF
Clin Cancer Res; 2024 Mar; 30(6):1200-1207. PubMed ID: 38180733
[TBL] [Abstract] [Full Text] [Related]
[Next]
